News und Analysen
GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID
GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis
Santhera: Endgültiger Studienstopp von DMD-Medikament
Dämpfer für Santhera Pharmaceuticals (WKN: A0LCUK): Die Schweizer Biotechschmiede stellt die zulassungsrelevante Phase-3-Studie mit Puldysa bei Patienten mit Duchenne-Muskeldystrophie (DMD) ein. Die
Santhera: Vamorolone droht zu scheitern – an der Konkurrenz!
Große Hoffnung setzen Anleger von Santhera (WKN: A0LCUK) in den einlizenzierten DMD-Medikamentenkandidaten Vamorolone und übersehen dabei offensichtlich völlig: Das Steroid wird in Zukunft
DGAP-News: Molecular Partners AG: Molecular Partners Successfully Completes the Launch of a Private Placement of 5,528,089 Shares by way of an Accelerated Bookbuilding
DGAP-News: Molecular Partners AG: Molecular Partners Successfully Completes the Launch of a Private Placement of 5,528,089 Shares by way of an Accelerated Bookbuilding
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Annual General Meeting of Kuros Biosciences approves all resolutions
Annual General Meeting of Kuros Biosciences approves all resolutions
Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected
Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected
Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules
Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules
Evolva Holding in liquidation SA publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports positive purchase price adjustment of CHF 1,929,000 under SPA; g
Evolva Holding in liquidation SA publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports positive purchase price adjustment of CHF 1,929,000 under SPA; g
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
Evolva Holding SA in liquidation: Nice & Green requests 3 agenda items be included in AGM agenda
Evolva Holding SA in liquidation: Nice & Green requests 3 agenda items be included in AGM agenda
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023
Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting
Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting
Evolva convenes extraordinary general meeting (EGM) for 21 December 2023 to approve the sale of Evolva AG to Lallemand Inc.
Evolva convenes extraordinary general meeting (EGM) for 21 December 2023 to approve the sale of Evolva AG to Lallemand Inc.
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
Evolva enters into an agreement to sell its operations to Lallemand, securing the best possible outcome for the company and its stakeholders
Evolva enters into an agreement to sell its operations to Lallemand, securing the best possible outcome for the company and its stakeholders
Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam
Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam
GeNeuro and Verily Collaborate to Advance Long-COVID Research
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announced a collaboration with Verily, an
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management